Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 19Glioma 5Neoplasms 4Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Ovarian Neoplasms 3Neuroblastoma 3Medulloblastoma 3Glioblastoma 3Colorectal Neoplasms 3Rhabdoid Tumor 2Lymphoma 2Lung Neoplasms 2Liposarcoma 2Diffuse Intrinsic Pontine Glioma 2Carcinoma, Ovarian Epithelial 2Brain Neoplasms 2Astrocytoma 2Stomach Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Rhabdomyosarcoma 1Pyloric Stenosis, Hypertrophic 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pinealoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Oligodendroglioma 1

Interventions

ribociclib 1LSZ102 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced or Metastatic ER+ Breast Cancer × ribociclib × Clear all
NCT02734615 2022-08-01

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

Novartis

Phase 1 Terminated
199 enrolled
Breast

Advanced or Metastatic ER+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡